Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1997-07-08
2001-11-13
Shah, Mukund J. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S570000, C548S566000, C548S567000
Reexamination Certificate
active
06316490
ABSTRACT:
The present invention relates to compounds which potentiate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to compounds that are capable of modulating acetylcholine receptors. Invention compounds are useful, for example, for treatment of dysfunction of the central and autonomic nervous systems (e.g. dementia, cognitive disorders, neurodegenerative disorders, extrapyramidal disorders, convulsive disorders, cardiovascular disorders, endocrine disorders, eating disorders, affective disorders, drug abuse, and the like). In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses therefor.
BACKGROUND OF THE INVENTION
By modulating neurotransmitter release (including dopamine, norepinephrine, acetylcholine and serotonin) from different brain regions, acetylcholine receptors are involved in the modulation of neuroendocrine function, respiration, mood, motor control and function, focus and attention, concentration, memory and cognition, and the mechanisms of substance abuse. Ligands for acetylcholine receptors have been demonstrated to have effects on attention, cognition, appetite, substance abuse, memory, extrapyramidal function, cardiovascular function, pain and gastrointestinal motility and function. The distribution of acetylcholine receptors that bind nicotine, i.e., nicotinic acetylcholine receptors, is widespread in the brain, including the basal ganglia, limbic system, cerebral cortex and mid- and hind-brain nuclei. In the periphery, the distribution includes muscle, autonomic ganglia, the gastrointestinal tract and the cardiovascular system.
Acetylcholine receptors have been shown to be decreased, inter alia, in the brains of patients suffering from Alzheimer's disease or Parkinson's disease, diseases associated with dementia, motor dysfunction and cognitive impairment. Such correlations between acetylcholine receptors and nervous system disorders suggest that compounds that modulate acetylcholine receptors will have beneficial therapeutic effects for many human nervous system disorders. Thus, there is a continuing need for compounds which have the ability to modulate the activity of acetylcholine receptors. In response to such need, the present invention provides a new family of compounds which modulate acetylcholine receptors.
BRIEF DESCRIPTION OF THE INVENTION
In accordance with the present invention, we have discovered a novel class of substituted aryl compounds (containing an ether, ester, amide, ketone or thioether functionality) that promote the release of ligands involved in neurotransmission. More particularly, compounds of the present invention are capable of modulating acetylcholine receptors.
The compounds of the present invention are capable of displacing one or more acetylcholine receptor ligands, e.g.,
3
H-nicotine, from mammalian neuronal membrane binding sites. In addition, invention compounds display activity in cell lines which express recombinant acetylcholine receptors. It can readily be seen, therefore, that invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors. Therapeutic indications for compounds with activity at acetylcholine receptors include diseases of the central nervous system such as Alzheimer's disease and other diseases involving memory loss and/or dementia (including AIDS dementia); cognitive dysfunction (including disorders of attention, focus and concentration), disorders of extrapyramidal motor function such as Parkinson's disease, progressive supramuscular palsy, Huntington's disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, anxiety and psychosis; substance abuse including withdrawal symptoms and substitution therapy; neurocrine disorders and dysregulation of food intake, including bulimia and anorexia; disorders or nociception and control of pain; autonomic disorders including dysfunction of gastrointestinal motility and function such as inflammatory bowel disease, irritable bowel syndrome, diarrhea, constipation, gastric acid secretion and ulcers; pheochromocytoma, cardiovascular dysfunction including hypertension and cardiac arrhythmias, as well as co-medication uses in surgical applications.
REFERENCES:
patent: 3247213 (1966-04-01), Büchel et al.
patent: 4048333 (1977-09-01), Galabov et al.
patent: 4155909 (1979-05-01), Sanders et al.
patent: 4321387 (1982-03-01), Chavdarian et al.
patent: 4965074 (1990-10-01), Leeson
patent: 5130309 (1992-07-01), Shanklin, Jr. et al.
patent: 5175301 (1992-12-01), Minamida et al.
patent: 5212188 (1993-05-01), Caldwell et al.
patent: 5214060 (1993-05-01), Caldwell et al.
patent: 5214152 (1993-05-01), Minamida et al.
patent: 5248690 (1993-09-01), Caldwell et al.
patent: 5278176 (1994-01-01), Lin
patent: 5399575 (1995-03-01), Friebe et al.
patent: 5418229 (1995-05-01), Alker et al.
patent: 5538956 (1996-07-01), Minchin et al.
patent: 5547991 (1996-08-01), Palfreyman et al.
patent: 5571832 (1996-11-01), de Costa et al.
patent: 2106895 (1994-03-01), None
patent: 1231704 (1967-01-01), None
patent: 0 302 389 A2 (1989-02-01), None
patent: 0 412 798 A2 (1991-02-01), None
patent: 0 427 636 A2 (1991-05-01), None
patent: 0 537 993 A1 (1993-04-01), None
patent: 0 559 495 A1 (1993-09-01), None
patent: 0 567 251 A1 (1993-10-01), None
patent: 0 600 373 A1 (1993-11-01), None
patent: 0 567 703 A1 (1993-11-01), None
patent: 0 568 208 A1 (1993-11-01), None
patent: 0 571 139 A1 (1993-11-01), None
patent: 0 575 048 A1 (1993-12-01), None
patent: 2714376 (1994-01-01), None
patent: WO 94/08992 (1904-04-01), None
patent: WO 92/15306 (1992-09-01), None
patent: WO 92/21339 (1992-12-01), None
patent: WO 93/22302 (1993-11-01), None
patent: WO 94/01435 (1994-01-01), None
patent: WO 94/05288 (1994-03-01), None
patent: WO 94/13291 (1994-06-01), None
patent: WO 94/18959 (1994-09-01), None
patent: WO 95/21615 (1995-08-01), None
patent: WO 96/32100 (1996-10-01), None
patent: WO 96/40095 (1996-12-01), None
patent: WO 96/40140 (1996-12-01), None
patent: WO 96/40633 (1996-12-01), None
Kaszubska et al., Chem. Abstract 101:54832, 1984.*
Bal et al., Chem. Abstract 99:5466, 1983.*
Aislaitner et al., “The Synthesis of 1′ -N-Methyl-2′ Oxoanabasine, an Analogue of Continine”,Bioorganic Med. Chem. Lett. 4 (3):515-520 (1994).
Albanese et al., “Chronic Administration of 1-Methyl-4-Phenyl-1, 2, 3, 6 -Tetrahdrophyridine to Monkeys: Behavioural, Morphological and Biochemical Correlates”,Neuroscience55 (3):823-932 (1993).
Aubert et al., “Comparative Alterations of Nicotinic and Muscarinic Binding Sites in Alzheimer's and Parkinson's Diseases”,J. Neurochem. 58 (2):529-541 (1992).
Borch et al., “The Cyanohydridoborate Anion as a Selective Reducing Agent”,J. Am. Chem. Soc. 93 (12):2897-2904 (1971).
Brioni et al., “Nicotinic Receptor Agonists Exhibit Anxiolytic-Like Effects on the Elevated Plus-Maze Test”,Eur. J. Pharmacol. 238:1-8 (1993).
Burk et al., “Preparation and Use of C2-Symmetric Bis (phospholanes): Production of &agr;-Amino Acid Derivatives via Highly Enantioselective Hyrdrogenation Reactions”,J. Am. Chem. Soc. 115:10125-10138 (1993).
Burk et al., “Catalytic Asymmetric Reductive Amination of Ketones via Highly Enantioselective Hydrogenation of the C=N Double Bond”,Tetrahedron50 (15): 4399-4428 (1994).
Chavdarian et al., “Synthesis of Optically Active Nicotinoids”J. Org. Chem. 47:1069-1073 (1982).
Cho and Chun, “Asymmetric Reduction of N-Substituted Ketimines with the Reagent prepared from Borane and (S)-(=)-2-Amino-3-methyl-1, 1-diphenylbutan-1-o1 (Itsuno's Reagent): Enantioselective Synthesis of Optically Active Secondary Amines”,J. Chem. Soc. Perk. 1:3200-3201 (1990).
Christensen et al., “On the Supersensitivity of Dopamine Receptors, Induced by Neuroleptics”,Psychoparmacol. 48:1-6 (1976).
Clow et al., “Changes in Dopamine-Medicated Behavior During One Year&ap
McDonald Ian A.
Vernier Jean-Michel
Lee Shu M.
Merck & Co. , Inc.
Rao Deepak R.
Rose David L.
Shah Mukund J.
LandOfFree
Substituted aryl compounds useful as modulators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted aryl compounds useful as modulators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted aryl compounds useful as modulators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2601967